CARLSBAD, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that its Board of
Directors has promoted B. Lynne Parshall, J.D. to Chief Operating Officer,
effective immediately. Ms. Parshall retains her position as Chief Financial
Officer, and is a Director of the Company.
"This promotion is well-deserved, and appropriately reflects the scope
of Lynne's responsibilities at Isis," commented Stanley Crooke, M.D.,
Ph.D., Isis' President and CEO. "Lynne has been an integral part of Isis'
management team for many years, and has been performing COO functions now
for quite some time. This promotion recognizes her outstanding
contributions and the nature of her current role with the Company."
Ms. Parshall joined Isis in November 1991, and she has served as
Director since 2000, Executive Vice President since 1995, Chief Financial
Officer since 1994 and Secretary since 1991. Ms. Parshall is currently
responsible for overseeing the operations of finance, legal, patents,
manufacturing and business development and is also very involved in the
Company's corporate communications activities. Previously, Ms. Parshall was
a Partner with the firm of Cooley Godward LLP, now Cooley Godward Kronish
LLP, where she represented several health care companies in a general
practice specializing in corporate partnering and other technology-based
transactions. Ms. Parshall received her J.D. at Stanford Law School,
Stanford, California and her B.A. from Harvard University, Cambridge,
Massachusetts. Ms. Parshall is on the board of CardioDynamics International
Corporation and is a Trustee of The Bishop School in La Jolla. Ms. Parshall
is also a member of the Licensing Executives Society and a member of the
American, California, and San Diego bar associations.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and has 18
drugs in development. Isis' drug development programs are focused on
treating cardiovascular and metabolic diseases. Isis' partners are
developing antisense drugs invented by Isis to treat a wide variety of
diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is
developing and commercializing the Ibis T5000(TM) Biosensor System, a
revolutionary system to identify infectious organisms. Isis is a joint
owner of Regulus Therapeutics LLC, a joint venture focused on the
discovery, development and commercialization of microRNA therapeutics. As
an innovator in RNA-based drug discovery and development, Isis is the owner
or exclusive licensee of over 1,500 issued patents worldwide. Additional
information about Isis is available at http://www.isispharm.com.
This press release includes forward-looking statements regarding Isis
Pharmaceuticals and the Company's business. Any statement describing Isis'
goals, expectations, financial or other projections, intentions or beliefs
is a forward-looking statement and should be considered an at-risk
statement, including those statements that are described as Isis' goals.
Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around such
products. Isis' forward-looking statements also involve assumptions that,
if they never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such forward- looking
statements. Although Isis' forward-looking statements reflect the good
faith judgment of its management, these statements are based only on facts
and factors currently known by Isis. As a result, you are cautioned not to
rely on these forward-looking statements. These and other risks concerning
Isis' programs are described in additional detail in Isis' annual report on
Form 10-K for the year ended December 31, 2006, and its quarterly report on
Form 10-Q for the quarter ended September 30, 2007, which are on file with
the SEC. Copies of these and other documents are available from the
Company.
In this press release, unless the context requires otherwise, "Isis,"
"Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its
subsidiaries.
Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals,
Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences,
Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.
| |
SOURCE Isis Pharmaceuticals, Inc.
 back to top
Related links:
http://www.isispharm.com
CONTACT:
Kristina Lemonidis, Associate Director,
Investor Relations, +1-760-603-2490, or Amy Blackley, Ph.D.,
Manager, Corporate Communications, +1-760-603-2772, both of Isis
Pharmaceuticals, Inc.
| |
|
